{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:13:31Z","timestamp":1780539211261,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00066-020-01582-3","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T14:02:41Z","timestamp":1580479361000},"page":"664-670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["An autoimmune-based, paraneoplastic neurologic syndrome following checkpoint inhibition and concurrent radiotherapy for merkel cell carcinoma: case report"],"prefix":"10.1007","volume":"196","author":[{"given":"Alexander D.","family":"Sherry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bezzerides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed H.","family":"Khattab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin K.","family":"Ancell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3807-6900","authenticated-orcid":false,"given":"Austin N.","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,31]]},"reference":[{"key":"1582_CR1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/bjd.14632","volume":"176","author":"JK Winkler","year":"2017","unstructured":"Winkler\u00a0JK, Bender\u00a0C, Kratochwil\u00a0C et al (2017) PD\u20111 blockade: a\u00a0therapeutic option for treatment of metastatic Merkel cell carcinoma. Br J Dermatol 176:216\u2013219. https:\/\/doi.org\/10.1111\/bjd.14632","journal-title":"Br J Dermatol"},{"key":"1582_CR2","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"P Nghiem","year":"2016","unstructured":"Nghiem\u00a0P, Bhatia\u00a0S, Lipson\u00a0E et al (2016) PD\u20111 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N\u00a0Engl J Med 374:2542\u20132552. https:\/\/doi.org\/10.1056\/NEJMoa1603702","journal-title":"N Engl J Med"},{"key":"1582_CR3","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman\u00a0HL, Russell\u00a0J, Hamid\u00a0O et al (2016) Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a\u00a0multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17:1374\u20131385. https:\/\/doi.org\/10.1016\/S1470-2045(16)30364-3","journal-title":"Lancet Oncol"},{"key":"1582_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1200\/JCO.18.01896","volume":"37","author":"P Nghiem","year":"2019","unstructured":"Nghiem\u00a0P, Bhatia\u00a0S, Lipson\u00a0EJ et al (2019) Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy. J\u00a0Clin Oncol 37:693\u2013702. https:\/\/doi.org\/10.1200\/JCO.18.01896","journal-title":"J Clin Oncol"},{"key":"1582_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejca.2016.10.022","volume":"71","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf\u00a0D, Lebb\u00e9\u00a0C, zur Hausen\u00a0A et\u00a0al (2017) Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer 71:53\u201369. https:\/\/doi.org\/10.1016\/j.ejca.2016.10.022","journal-title":"Eur J Cancer"},{"key":"1582_CR6","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1158\/1078-0432.CCR-17-0439","volume":"24","author":"A Colunga","year":"2018","unstructured":"Colunga\u00a0A, Pulliam\u00a0T, Nghiem\u00a0P (2018) Merkel cell carcinoma in the age of immunotherapy: facts and hopes. Clin Cancer Res 24:2035\u20132043. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0439","journal-title":"Clin Cancer Res"},{"key":"1582_CR7","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/jid.2012.388","volume":"133","author":"KG Paulson","year":"2013","unstructured":"Paulson\u00a0KG, Iyer\u00a0JG, Blom\u00a0A et al (2013) Systemic immune suppression predicts diminished merkel cell carcinoma-specific survival independent of stage. J\u00a0Invest Dermatol 133:642\u2013646. https:\/\/doi.org\/10.1038\/jid.2012.388","journal-title":"J Invest Dermatol"},{"key":"1582_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fonc.2019.00020","volume":"9","author":"J von der Gr\u00fcn","year":"2019","unstructured":"von der Gr\u00fcn\u00a0J, Winkelmann\u00a0R, Meissner\u00a0M et\u00a0al (2019) Merkel cell polyoma viral load and Intratumoral CD8+ lymphocyte infiltration predict overall survival in patients with Merkel cell carcinoma. Front Oncol 9:20. https:\/\/doi.org\/10.3389\/fonc.2019.00020","journal-title":"Front Oncol"},{"key":"1582_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3389\/fonc.2019.00223","volume":"9","author":"BC Bloom","year":"2019","unstructured":"Bloom\u00a0BC, Augustyn\u00a0A, Pezzi\u00a0TA et al (2019) Rescue of immunotherapy-refractory metastatic Merkel cell carcinoma with conventionally fractionated radiotherapy and concurrent pembrolizumab. Front Oncol 9:223. https:\/\/doi.org\/10.3389\/fonc.2019.00223","journal-title":"Front Oncol"},{"key":"1582_CR10","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1080\/09553002.2019.1623429","volume":"95","author":"EC Ko","year":"2019","unstructured":"Ko\u00a0EC, Formenti\u00a0SC (2019) Radiation therapy to enhance tumor immunotherapy: a\u00a0novel application for an established modality. Int J Radiat Biol 95:936\u2013939. https:\/\/doi.org\/10.1080\/09553002.2019.1623429","journal-title":"Int J Radiat Biol"},{"key":"1582_CR11","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh\u00a0L, Ghiringhelli\u00a0F, Tesniere\u00a0A et al (2007) Toll-like receptor 4\u2011dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050\u20131059. https:\/\/doi.org\/10.1038\/nm1622","journal-title":"Nat Med"},{"key":"1582_CR12","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","volume":"71","author":"BC Burnette","year":"2011","unstructured":"Burnette\u00a0BC, Liang\u00a0H, Lee\u00a0Y et al (2011) The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res 71:2488\u20132496. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2820","journal-title":"Cancer Res"},{"key":"1582_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","volume":"24","author":"F Klug","year":"2013","unstructured":"Klug\u00a0F, Prakash\u00a0H, Huber\u00a0PE et al (2013) Low-dose irradiation programs macrophage differentiation to an iNOS+\/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24:589\u2013602. https:\/\/doi.org\/10.1016\/j.ccr.2013.09.014","journal-title":"Cancer Cell"},{"key":"1582_CR14","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.4049\/jimmunol.181.5.3099","volume":"181","author":"S Matsumura","year":"2008","unstructured":"Matsumura\u00a0S, Wang\u00a0B, Kawashima\u00a0N et al (2008) Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J\u00a0Immunol 181:3099\u20133107. https:\/\/doi.org\/10.4049\/jimmunol.181.5.3099","journal-title":"J Immunol"},{"key":"1582_CR15","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","volume":"203","author":"EA Reits","year":"2006","unstructured":"Reits\u00a0EA, Hodge\u00a0JW, Herberts\u00a0CA et\u00a0al (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J\u00a0Exp Med 203:1259\u20131271. https:\/\/doi.org\/10.1084\/jem.20052494","journal-title":"J Exp Med"},{"key":"1582_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot\u00a0JM, Bigenwald\u00a0C, Champiat\u00a0S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.016","journal-title":"Eur J Cancer"},{"key":"1582_CR17","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson\u00a0DB, Balko\u00a0JM, Compton\u00a0ML et\u00a0al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N\u00a0Engl J Med 375:1749\u20131855. https:\/\/doi.org\/10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"1582_CR18","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1200\/JCO.2003.03.154","volume":"21","author":"M Poulsen","year":"2003","unstructured":"Poulsen\u00a0M, Rischin\u00a0D, Walpole\u00a0E et al (2003) High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin\/etoposide and radiation: a trans-tasman radiation oncology group study-TROG 96:07. J\u00a0Clin Oncol 21:4371\u20134376. https:\/\/doi.org\/10.1200\/JCO.2003.03.154","journal-title":"J Clin Oncol"},{"key":"1582_CR19","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1001\/archdermatol.2011.176","volume":"147","author":"SE Cotter","year":"2011","unstructured":"Cotter\u00a0SE, Dunn\u00a0GP, Collins\u00a0KM et\u00a0al (2011) Abscopal effect in a\u00a0patient with metastatic Merkel cell carcinoma following radiation therapy: potential role of induced antitumor immunity. Arch Dermatol 147:870\u2013872. https:\/\/doi.org\/10.1001\/archdermatol.2011.176","journal-title":"Arch Dermatol"},{"key":"1582_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40425-018-0396-9","volume":"6","author":"J Appelbaum","year":"2018","unstructured":"Appelbaum\u00a0J, Wells\u00a0D, Hiatt\u00a0JB et\u00a0al (2018) Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. J\u00a0Immunother Cancer 6:82. https:\/\/doi.org\/10.1186\/s40425-018-0396-9","journal-title":"J Immunother Cancer"},{"key":"1582_CR21","doi-asserted-by":"crossref","first-page":"P5.409","DOI":"10.1212\/WNL.90.15_supplement.P5.409","volume":"90","author":"B Santomasso","year":"2018","unstructured":"Santomasso\u00a0B, D\u2019Angelo\u00a0S (2018) Anti-CRMP5-associated paraneoplastic neurologic syndrome developing in a\u00a0patient with metastatic Merkel cell carcinoma during immune checkpoint inhibitor treatment. Neurology 90:P5.409","journal-title":"Neurology"},{"key":"1582_CR22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","volume":"30","author":"M Touat","year":"2017","unstructured":"Touat\u00a0M, Talmasov\u00a0D, Ricard\u00a0D, Psimaras\u00a0D (2017) Neurological toxicities associated with immune-checkpoint inhibitors. Curr Opin Neurol 30:659\u2013668. https:\/\/doi.org\/10.1097\/WCO.0000000000000503","journal-title":"Curr Opin Neurol"},{"key":"1582_CR23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.intimp.2018.08.014","volume":"63","author":"B Zhang","year":"2018","unstructured":"Zhang\u00a0B, Wu\u00a0Q, Zhou\u00a0YL et al (2018) Immune-related adverse events from combination immunotherapy in cancer patients: a comprehensive meta-analysis of randomized controlled trials. Int J Immunopharmacol 63:292\u2013298. https:\/\/doi.org\/10.1016\/j.intimp.2018.08.014","journal-title":"Int. J. Immunopharmacol."},{"key":"1582_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semradonc.2014.07.005","volume":"25","author":"EB Golden","year":"2015","unstructured":"Golden\u00a0EB, Apetoh\u00a0L (2015) Radiotherapy and immunogenic cell death. Semin Radiat Oncol 25:11\u201317. https:\/\/doi.org\/10.1016\/j.semradonc.2014.07.005","journal-title":"Semin Radiat Oncol"},{"key":"1582_CR25","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2217\/imt.15.65","volume":"7","author":"SN Seyedin","year":"2015","unstructured":"Seyedin\u00a0SN, Schoenhals\u00a0JE, Lee\u00a0DA et\u00a0al (2015) Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy 7:967\u2013980. https:\/\/doi.org\/10.2217\/imt.15.65","journal-title":"Immunotherapy"},{"key":"1582_CR26","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.trecan.2016.09.007","volume":"2","author":"W Jiang","year":"2016","unstructured":"Jiang\u00a0W, Chan\u00a0CK, Weissman\u00a0IL et\u00a0al (2016) Immune priming of the tumor microenvironment by radiation. Trends Cancer 2:638\u2013645. https:\/\/doi.org\/10.1016\/j.trecan.2016.09.007","journal-title":"Trends Cancer"},{"key":"1582_CR27","doi-asserted-by":"publisher","first-page":"e954929","DOI":"10.4161\/21624011.2014.954929","volume":"3","author":"N Bloy","year":"2014","unstructured":"Bloy\u00a0N, Pol\u00a0J, Manic\u00a0G et\u00a0al (2014) Trial watch: radioimmunotherapy for oncological indications. OncoImmunology 3:e954929. https:\/\/doi.org\/10.4161\/21624011.2014.954929","journal-title":"OncoImmunology"},{"key":"1582_CR28","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41571-018-0046-7","volume":"15","author":"WL Hwang","year":"2018","unstructured":"Hwang\u00a0WL, Pike\u00a0LRG, Royce\u00a0TJ et al (2018) Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol 15:477\u2013494. https:\/\/doi.org\/10.1038\/s41571-018-0046-7","journal-title":"Nat Rev Clin Oncol"},{"key":"1582_CR29","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1016\/j.ijrobp.2009.05.071","volume":"76","author":"BD Kavanagh","year":"2010","unstructured":"Kavanagh\u00a0BD, Pan\u00a0CC, Dawson\u00a0LA et al (2010) Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys 76:S101\u2013S107. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.05.071","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1582_CR30","volume-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines): gastric cancer version 2.2018","author":"NCCN","year":"2018","unstructured":"NCCN (2018) NCCN clinical practice guidelines in oncology (NCCN guidelines): gastric cancer version 2.2018"},{"key":"1582_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","volume":"86","author":"LA Kachnic","year":"2013","unstructured":"Kachnic\u00a0LA, Winter\u00a0K, Myerson\u00a0RJ et al (2013) RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5\u2011fluorouracil and mitomycin\u2011C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 86:27\u201333. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.09.023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1582_CR32","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.ijrobp.2012.09.036","volume":"85","author":"R Banerjee","year":"2013","unstructured":"Banerjee\u00a0R, Chakraborty\u00a0S, Nygren\u00a0I, Sinha\u00a0R (2013) Small bowel dose parameters predicting grade \u22653 acute toxicity in rectal cancer patients treated with neoadjuvant chemoradiation: an independent validation study comparing peritoneal space versus small bowel loop contouring techniques. Int J Radiat Oncol Biol Phys 85:1225\u20131231. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.09.036","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1582_CR33","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","volume":"16","author":"B Liao","year":"2014","unstructured":"Liao\u00a0B, Shroff\u00a0S, Kamiya-Matsuoka\u00a0C, Tummala\u00a0S (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16:589\u2013593. https:\/\/doi.org\/10.1093\/neuonc\/nou001","journal-title":"Neuro Oncol"},{"key":"1582_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/ana.10225","volume":"52","author":"JE Greenlee","year":"2002","unstructured":"Greenlee\u00a0JE, Steffens\u00a0JD, Clawson\u00a0SA et al (2002) Anti-Hu antibodies in Merkel cell carcinoma. Ann Neurol 52:111\u2013115. https:\/\/doi.org\/10.1002\/ana.10225","journal-title":"Ann Neurol"},{"key":"1582_CR35","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","volume":"29","author":"A Hottinger","year":"2016","unstructured":"Hottinger\u00a0A (2016) Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 29:806\u2013812. https:\/\/doi.org\/10.1097\/WCO.0000000000000391","journal-title":"Curr Opin Neurol"},{"key":"1582_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4065\/76.3.327","volume":"76","author":"SDZ Eggers","year":"2001","unstructured":"Eggers\u00a0SDZ, Salomao\u00a0DR, Dinapoli\u00a0RP, Vernino\u00a0S (2001) Paraneoplastic and metastatic neurologic complications of Merkel cell carcinoma. Mayo Clin Proc 76:327\u2013330. https:\/\/doi.org\/10.4065\/76.3.327","journal-title":"Mayo Clin Proc"},{"key":"1582_CR37","doi-asserted-by":"publisher","first-page":"175628641879986","DOI":"10.1177\/1756286418799864","volume":"11","author":"MC Dalakas","year":"2018","unstructured":"Dalakas\u00a0MC (2018) Neurological complications of immune checkpoint inhibitors: what happens when you \u2018take the brakes off\u2019 the immune system. Ther Adv Neurol Disord 11:1756286418799864. https:\/\/doi.org\/10.1177\/1756286418799864","journal-title":"Ther Adv Neurol Disord"},{"key":"1582_CR38","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.lungcan.2017.07.025","volume":"111","author":"L Ruelle","year":"2017","unstructured":"Ruelle\u00a0L, Bentea\u00a0G, Sideris\u00a0S et\u00a0al (2017) Autoimmune paraneoplastic syndromes associated to lung cancer: a systematic review of the literature part 4: neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles. Lung Cancer 111:150\u2013163. https:\/\/doi.org\/10.1016\/j.lungcan.2017.07.025","journal-title":"Lung Cancer"},{"key":"1582_CR39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/CJI.0b013e318193a206","volume":"32","author":"S Bhatia","year":"2009","unstructured":"Bhatia\u00a0S, Huber\u00a0BR, Upton\u00a0MP, Thompson\u00a0JA (2009) Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J\u00a0Immunother 32:203\u2013205. https:\/\/doi.org\/10.1097\/CJI.0b013e318193a206","journal-title":"J Immunother"},{"key":"1582_CR40","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jaad.2016.04.040","volume":"75","author":"JG Iyer","year":"2016","unstructured":"Iyer\u00a0JG, Parvathaneni\u00a0K, Bhatia\u00a0S et\u00a0al (2016) Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): a case series of 8 patients highlighting different clinical manifestations. J\u00a0Am Acad Dermatol 75:541\u2013547. https:\/\/doi.org\/10.1016\/j.jaad.2016.04.040","journal-title":"J Am Acad Dermatol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-020-01582-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00066-020-01582-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-020-01582-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T22:15:01Z","timestamp":1722377701000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00066-020-01582-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,31]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1582"],"URL":"https:\/\/doi.org\/10.1007\/s00066-020-01582-3","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,31]]},"assertion":[{"value":"12 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"M.H.\u00a0Khattab reports research funding from Varian Medical Systems and Brainlab. A.D.\u00a0Sherry, M.\u00a0Bezzerides, G.\u00a0Luo, K.K.\u00a0Ancell, and A.N.\u00a0Kirschner declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was exempt from IRB review per VUMC IRB Policy I.B.1. All identifiable patient information has been omitted, and the information contained in the manuscript is anonymized. The patient reported in this study provided written informed consent authorizing use and disclosure of his protected health information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}